Brain Cancer Clinical Trials in Cleveland

Showing 181-186 of 186 trials

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

NCT00089427

This Phase 1 study in patients with newly diagnosed malignant glioma is designed to determine the highest dose of IL13-PE38QQR that can be safely administered by Convection Enhanced Delivery (CED) to the area around the tumor site after the tumor is surgically removed (resection). In addition, the patient will receive radiation therapy and may or may not be treated with oral temozolomide.

Glioblastoma MultiformeAnaplastic AstrocytomaOligoastrocytoma

INSYS Therapeutics Inc24 participantsStarted Jul 2004

San Francisco, California, United States • Charlotte, North Carolina, United States • Durham, North Carolina, United States +3 more locations

COMPLETEDPhase 3115 miles

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

NCT00068952

The purpose of this clinical trial is to study Edotecarin in patients with the brain tumor glioblastoma multiforme (GBM) who have progression or first recurrence following initial treatment with surgery, radiation and chemotherapy.

Glioblastoma

Pfizer118 participantsStarted Aug 2003

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • New Haven, Connecticut, United States +49 more locations

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

Brain Cancer Trials in Other Cities

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme

A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

Other Conditions in Cleveland